ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 876-900 of 1,000 matching filings.

Per page
25
Current page
36
6-K File 001-11960

ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED

Filing date
02 Apr 2020
Reporting date
02 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Apr 2020
Reporting date
01 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
31 Mar 2020
Reporting date
31 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA

Filing date
30 Mar 2020
Reporting date
30 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Filing date
30 Mar 2020
Reporting date
30 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
26 Mar 2020
Reporting date
26 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA

Filing date
26 Mar 2020
Reporting date
26 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
20 Mar 2020
Reporting date
20 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA

Filing date
19 Mar 2020
Reporting date
19 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE

Filing date
17 Mar 2020
Reporting date
17 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

6-K

Filing date
12 Mar 2020
Reporting date
12 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NOTICE OF AGM

Filing date
12 Mar 2020
Reporting date
12 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS

Filing date
12 Mar 2020
Reporting date
12 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
10 Mar 2020
Reporting date
10 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S

Filing date
06 Mar 2020
Reporting date
06 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FILING OF FORM 20-F WITH SEC

Filing date
04 Mar 2020
Reporting date
04 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
IRANNOTICE File 001-11960

IRANNOTICE

Filing date
03 Mar 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ANNUAL FINANCIAL REPORT

Filing date
03 Mar 2020
Reporting date
03 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Mar 2020
Reporting date
02 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY

Filing date
02 Mar 2020
Reporting date
02 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
27 Feb 2020
Reporting date
27 Feb 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK

Filing date
25 Feb 2020
Reporting date
25 Feb 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
19 Feb 2020
Reporting date
19 Feb 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: FULL-YEAR AND Q4 2019 RESULTS

Filing date
14 Feb 2020
Reporting date
14 Feb 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .